Zobrazeno 1 - 10
of 64
pro vyhledávání: '"SLOBODANKA OSTOJIĆ KOLONIĆ"'
Autor:
Vibor Milunović, Ida Hude, Goran Rinčić, Davor Galušić, Aron Grubešić, Marko Martinović, Nika Popović, Sunčana Divošević, Klara Brčić, Marin Međugorac, Luka Kužat, Dejan Strahija, Stefan Mrđenović, Inga Mandac Smoljanović, Delfa Radić-Krišto, Slavko Gašparov, Igor Aurer, Slobodanka Ostojić Kolonić
Publikováno v:
Biomedicines, Vol 10, Iss 11, p 2917 (2022)
Elderly patients make up a significant number of cases of newly diagnosed Hodgkin lymphoma. However, unlike in young patients, the outcomes of elderly patients are poor, and they are under-represented in phase III trials. Prior to treatment initiatio
Externí odkaz:
https://doaj.org/article/74e8d76b553144d3adb32d6f43e07fdb
Autor:
Suzana Hančić, Paula Gršković, Slavko Gašparov, Slobodanka Ostojić Kolonić, Mara Dominis, Petra Korać
Publikováno v:
Biomedicines, Vol 10, Iss 3, p 579 (2022)
Hodgkin lymphoma (HL) is a biologically diverse group of lymphoid tumors, which accounts for 1% of all de novo neoplasms in the world’s population. It is divided into two main groups: the more common classic Hodgkin lymphoma (cHL) and the less comm
Externí odkaz:
https://doaj.org/article/30f0df3d70ad4d8e885b4ce963bd8aa6
Autor:
Martina Bogeljić Patekar, Vibor Milunović, Karla Mišura Jakobac, Dražen Perica, Inga Mandac Rogulj, Marin Kursar, Ana Planinc-Peraica, Slobodanka Ostojić Kolonić
Publikováno v:
Acta Clinica Croatica, Vol 57., Iss 3., Pp 542-553 (2018)
The aim of this review is to present data on bendamustine, a non-cross resistant alkylating agent, alone or in combination for treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Bendamustine is currently approved for ritu
Externí odkaz:
https://doaj.org/article/a532d7dede5040d49da04c819b38aa99
Autor:
Vibor Milunović, Martina Bogeljić Patekar, Karla Mišura Jakubac, Inga Mandac Rogulj, Delfa Radić-Krišto, Ana Planinc-Peraica, Slobodanka Ostojić Kolonić
Publikováno v:
Acta Clinica Croatica, Vol 56., Iss 1., Pp 143-156 (2017)
Rituximab is a chimeric monoclonal CD20 antibody used in the treatment of CD20 positive non-Hodgkin lymphomas and has revolutionized treatment approach to these hematologic malignancies in the last decade. The main aim of this review is to present da
Externí odkaz:
https://doaj.org/article/56a6185676fe49db91e004668b948a8e
Autor:
Vibor Milunović, Inga Mandac Smoljanović, Martina Bogeljić Patekar, Viktor Zatezalo, Marin Kursar, Delfa Radić-Krišto, Slobodanka Ostojić Kolonić, Slavko Gašparov
Publikováno v:
Current Oncology Reports.
Purposeof review: The main aim of this review is to summarize first-line therapy of nodal T-cell non-Hodgkin lymphoma. Recent findings: Current treatment with CHOP chemotherapy results in poor outcomes in the majority of patients. However, there are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fe2ae5ed061c188ac2bbf4f89d786bb
https://doi.org/10.1007/s11912-023-01400-w
https://doi.org/10.1007/s11912-023-01400-w
Autor:
Inga Mandac Rogulj, Vibor Milunović, Delfa Radić-Krišto, Karla Mišura Jakobac, Slobodanka Ostojić Kolonić, Marko Martinović
Publikováno v:
Expert Review of Hematology. 13:771-779
Introduction: Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries occurring typically in elderly patients. These patients often present with comorbidities limiting treatment options. During the last decade, the treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::549545f212fe4be40202bc8907dd52b9
https://doi.org/10.1080/17474086.2020.1775575
https://doi.org/10.1080/17474086.2020.1775575
Elderly patients make up a significant number of cases of newly diagnosed Hodgkin lymphoma. However, unlike in young patients, the outcomes of elderly patients are poor, and they are under- represented in phase III trials. Prior to treatment initiati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::7dc42f0060e7d2baca043c4783cf22ae
https://www.bib.irb.hr/1270299
https://www.bib.irb.hr/1270299
Autor:
Paula, Gršković, Suzana, Hančić, Snježana, Dotlić, Maja, Matulić, Slobodanka, Ostojić Kolonić, Slavko, Gašparov, Mara, Dominis, Petra, Korać
Follicular lymphoma is the second most frequent non-Hodgkin's lymphoma, accounting for around 20 % of all lymphomas in Western countries. Initially, it behaves indolently, but in time becomes more aggressive and less susceptible to chemotherapy. Mult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b32c0ba7efe745bf829d5a02abe9c11e
https://www.bib.irb.hr/1211675
https://www.bib.irb.hr/1211675
Autor:
Petar Gaćina, Ivan Kruljac, Slobodanka Ostojić Kolonić, Milan Vrkljan, Kristina Blaslov, Gorana Mirošević
Publikováno v:
Clinical Hemorheology and Microcirculation. 71:475-481
BACKGROUNDAlthough it is considered that the pathogenesis of diabetic retinopathy (DR) in type 2 diabetes mellitus (T2DM) is primarily due to chronic hyperglycemia resulting in vascular changes and retinal ischemia, the red blood cells (RBCs) disorde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9666c103fcd35acce0e40dc261436239
https://doi.org/10.3233/ch-180422
https://doi.org/10.3233/ch-180422
Autor:
Inga Mandac-Rogulj, Duška Petranović, Marijo Vodanović, Jelena Roganović, Vlatko Pejša, Toni Valković, Ivo Radman, Igor Aurer, Slobodanka Ostojić Kolonić, Rajko Kusec
Publikováno v:
Liječnički vjesnik. 141:1-13
Iron deficiency anemia (IDA) is an important public health problem. Almost 30% of the world’s population (> 2 billion) has iron deficiency (ID) with or without anemia. Treatment of IDA requires teamwork. It is important to treat anemia and the unde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f9a31c09296b82db8745c8deb8c26527
https://doi.org/10.26800/lv-141-1-2-1
https://doi.org/10.26800/lv-141-1-2-1